Phenom Named Strategic Leader in 2024 Fosway 9-Grid™ for Talent & People Success
10.10.2024 11:30:00 CEST | Business Wire | Press release
Positioning Recognises Phenom’s Impact on Helping Europe’s Largest Companies Solve HR’s Biggest Talent Management Challenges
Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010930504/en/

Phenom has been named a Strategic Leader in the 2024 Fosway 9-Grid™ for Talent and People Success, a testament to the value delivered by the AI-powered Phenom Intelligent Talent Experience platform, which makes new employees productive faster, enhances development and increases retention. (Graphic: Business Wire)
Fosway Group identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. Strategic Leaders are also recognised by Fosway Group for having strong market performance and customer advocacy; as a result, they are frequently selected by such organisations and consistently meet their needs.
From labour shortages to changing skills and emerging technologies, the European job market continues to transform. To navigate this, talent management professionals, HR leaders and HRIT teams must collaborate to make new employees productive from day one, provide continued development opportunities, identify and fill skills gaps and encourage long-term retention.
“As European organisations wrestle with how they become more skills-based, they have been looking at how their tech stack solves that problem,” said David Wilson, CEO and founder of Fosway Group. “With their roots in skill-based hiring and their growing specialist capability around internal mobility and skills intelligence, Phenom has been well placed to provide a springboard to those answers for enterprise buyers. And their growing service and platform maturity has been pivotal in making them a Strategic Leader for talent experience on the Fosway 9-Grid™ this year.”
Phenom’s solution for talent and people success centers around delivering hyper-personalised experiences for employees, their managers and talent management. These experiences are enhanced with X+, Phenom’s Generative AI that is purpose-built for HR, to support key areas including:
- Pre-boarding: Provides a streamlined, transparent and easy experience that makes a lasting positive impact for new employees.
- Onboarding: Shortens time to productivity for new employees and automates tedious, manual tasks for HR teams.
- Talent Marketplace: Gives employees visibility to internal job and growth opportunities, as well as refers quality talent for critical roles.
- Career Pathing: Helps employees discover their next internal career move and the skills needed to get there. X+ provides an always on career coach that responds to their questions with personalised development plans.
- Cross-boarding: Supports employee transitions to new positions and teams.
- Workforce Intelligence: Identifies skill and competency gaps and insights within each department and at the enterprise level.
- Learning and Development: Educates internal talent with personalised courses to support upskilling and reskilling based on their projected career paths.
- Mentoring: Empowers and supports employees throughout their career journey by connecting them with best-fit mentors.
- Gigs: Provides real-world experience through short-term work and project-based tasks allowing employees to develop their skills.
- Employee Resource Groups: Fosters engagement, community and a sense of belonging.
- Offboarding: Streamlines experiences for employees leaving the organisation.
“Phenom’s positioning is a testament to our ongoing innovation and helping European organisations embrace a skills-based approach to talent management, growth and retention,” said John Deal, Sr. Director, Product Marketing at Phenom. “As Europe contends with an evolving workforce landscape, it has never been more critical to leverage intelligence to enable smarter and more impactful career development, upskilling and workforce planning decisions.”
Phenom’s placement also complements the company’s four-year positioning as a Strategic Leader in the Fosway 9-Grid™ for Talent Acquisition, showcasing the end-to-end benefits of using its full Intelligent Talent Experience platform. Over 700 global and diverse companies are using the Phenom platform to help:
- Candidates find and choose the right job faster.
- Employees develop their skills and evolve.
- Recruiters become wildly productive.
- Talent marketers engage with extreme efficiency.
- Talent leaders optimise hiring processes.
- Managers build stronger-performing teams.
- HR aligns employee development with company goals.
- HRIT easily integrates existing HR tech to create a holistic infrastructure.
See why Phenom continues to be recognised as industry leading, book a demo.
Click here for a personalised demo of Phenom’s Workforce Intelligence solution to learn more about how to set your employees up for career success.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire and onboard employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIT — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, X+ Screening, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Onboarding, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (5 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimising HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010930504/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom